

# Alessia Ciarrocchi

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5048533/publications.pdf>

Version: 2024-02-01

93  
papers

3,895  
citations

186265

28  
h-index

128289

60  
g-index

95  
all docs

95  
docs citations

95  
times ranked

5877  
citing authors

#	ARTICLE	IF	CITATIONS
1	OVOL2 impairs RHO GTPase signaling to restrain mitosis and aggressiveness of Anaplastic Thyroid Cancer. <i>Journal of Experimental and Clinical Cancer Research</i> , 2022, 41, 108.	8.6	6
2	Lift the curtain on long non-coding RNAs in hematological malignancies: Pathogenic elements and potential targets. <i>Cancer Letters</i> , 2022, 536, 215645.	7.2	7
3	A multimodal integrative approach to model transcriptional addiction of thyroid cancer on RUNX2. <i>Cancer Communications</i> , 2022, 42, 892-896.	9.2	5
4	Prognostic value of lesion dissemination in doxorubicin, bleomycin, vinblastine, and dacarbazine-treated, interimPET-negative classical Hodgkin Lymphoma patients: A radio-genomic study. <i>Hematological Oncology</i> , 2022, 40, 645-657.	1.7	19
5	The multifaceted role of EGLN family prolyl hydroxylases in cancer: going beyond HIF regulation. <i>Oncogene</i> , 2022, 41, 3665-3679.	5.9	9
6	MiR-146b-5p regulates IL-23 receptor complex expression in chronic lymphocytic leukemia cells. <i>Blood Advances</i> , 2022, 6, 5593-5612.	5.2	3
7	Linc00941 Is a Novel Transforming Growth Factor $\beta$ Target That Primes Papillary Thyroid Cancer Metastatic Behavior by Regulating the Expression of Cadherin 6. <i>Thyroid</i> , 2021, 31, 247-263.	4.5	31
8	Coexisting well-differentiated and anaplastic thyroid carcinoma in the same primary resection specimen: immunophenotypic and genetic comparison of the two components in a consecutive series of 13 cases and a review of the literature. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2021, 478, 265-281.	2.8	25
9	YAP and TAZ Are Not Identical Twins. <i>Trends in Biochemical Sciences</i> , 2021, 46, 154-168.	7.5	82
10	Gene expression profile unveils diverse biological effect of serum vitamin D in Hodgkin's and diffuse large B-cell lymphoma. <i>Hematological Oncology</i> , 2021, 39, 205-214.	1.7	6
11	Long Noncoding RNA <i>NEAT1</i> Acts as a Molecular Switch for BRD4 Transcriptional Activity and Mediates Repression of BRD4/WDR5 Target Genes. <i>Molecular Cancer Research</i> , 2021, 19, 799-811.	3.4	13
12	Cytoskeleton Dynamics in Peripheral T Cell Lymphomas: An Intricate Network Sustaining Lymphomagenesis. <i>Frontiers in Oncology</i> , 2021, 11, 643620.	2.8	0
13	An integrative functional genomics approach reveals EGLN1 as a novel therapeutic target in KRAS mutated lung adenocarcinoma. <i>Molecular Cancer</i> , 2021, 20, 63.	19.2	8
14	Molecular Fingerprints of Malignant Pleural Mesothelioma: Not Just a Matter of Genetic Alterations. <i>Journal of Clinical Medicine</i> , 2021, 10, 2470.	2.4	8
15	CSNK1A1, KDM2A, and LTB4R2 Are New Druggable Vulnerabilities in Lung Cancer. <i>Cancers</i> , 2021, 13, 3477.	3.7	4
16	The DNA-helicase HELLS drives ALK <sup>+</sup> ALCL proliferation by the transcriptional control of a cytokinesis-related program. <i>Cell Death and Disease</i> , 2021, 12, 130.	6.3	10
17	The transcription factor NF- $\kappa$ B participates to stem cell fate decision and regeneration in adult skeletal muscle. <i>Nature Communications</i> , 2021, 12, 6013.	12.8	12
18	No Need to Stick Together to Be Connected: Multiple Types of Enhancers <sup>TM</sup> Networking. <i>Cancers</i> , 2021, 13, 5201.	3.7	2

#	ARTICLE	IF	CITATIONS
19	Alternative splicing of NF-YA promotes prostate cancer aggressiveness and represents a new molecular marker for clinical stratification of patients. <i>Journal of Experimental and Clinical Cancer Research</i> , 2021, 40, 362.	8.6	18
20	Unexpected Widespread Bone Metastases from a BRAF K601N Mutated Follicular Thyroid Carcinoma within a Previously Resected Multinodular Goiter. <i>Endocrine Pathology</i> , 2021, . .	9.0	1
21	Survival results in biphasic malignant pleural mesothelioma patients: A multicentric analysis. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2020, 159, 1584-1593.e2.	0.8	14
22	A Gene Expression-based Model to Predict Metabolic Response After Two Courses of ABVD in Hodgkin Lymphoma Patients. <i>Clinical Cancer Research</i> , 2020, 26, 373-383.	7.0	11
23	RAIN Is a Novel Enhancer-Associated lncRNA That Controls RUNX2 Expression and Promotes Breast and Thyroid Cancer. <i>Molecular Cancer Research</i> , 2020, 18, 140-152.	3.4	19
24	Exploring metabolic reprogramming in melanoma via acquired resistance to the oxidative phosphorylation inhibitor phenformin. <i>Melanoma Research</i> , 2020, 30, 1-13.	1.2	6
25	Mutational Profile of Malignant Pleural Mesothelioma (MPM) in the Phase II RAMES Study. <i>Cancers</i> , 2020, 12, 2948.	3.7	14
26	Deep Sequencing Analysis Identified a Specific Subset of Mutations Distinctive of Biphasic Malignant Pleural Mesothelioma. <i>Cancers</i> , 2020, 12, 2454.	3.7	6
27	Acute Radiation Colitis after Preoperative Short-Course Radiotherapy for Rectal Cancer: A Morphological, Immunohistochemical and Genetic Study. <i>Cancers</i> , 2020, 12, 2571.	3.7	3
28	miR-196B-5P and miR-200B-3P Are Differentially Expressed in Medulloblastomas of Adults and Children. <i>Diagnostics</i> , 2020, 10, 265.	2.6	6
29	The novel lncRNA BlackMamba controls the neoplastic phenotype of ALK <sup>+</sup> anaplastic large cell lymphoma by regulating the DNA helicase HELLS. <i>Leukemia</i> , 2020, 34, 2964-2980.	7.2	13
30	Multiple roles and context-specific mechanisms underlying YAP and TAZ-mediated resistance to anti-cancer therapy. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2020, 1873, 188341.	7.4	20
31	Genomic analysis in short- and long-term patients with malignant pleura mesothelioma treated with palliative chemotherapy. <i>European Journal of Cancer</i> , 2020, 132, 104-111.	2.8	6
32	HDACs control RUNX2 expression in cancer cells through redundant and cell context-dependent mechanisms. <i>Journal of Experimental and Clinical Cancer Research</i> , 2019, 38, 346.	8.6	13
33	The Hippo pathway modulates resistance to BET proteins inhibitors in lung cancer cells. <i>Oncogene</i> , 2019, 38, 6801-6817.	5.9	54
34	Quick assessment of cell-free DNA in seminal fluid and fragment size for early non-invasive prostate cancer diagnosis. <i>Clinica Chimica Acta</i> , 2019, 497, 76-80.	1.1	27
35	Angiosarcoma and anaplastic carcinoma of the thyroid are two distinct entities: a morphologic, immunohistochemical, and genetic study. <i>Modern Pathology</i> , 2019, 32, 787-798.	5.5	26
36	Telomerase and Telomeres Biology in Thyroid Cancer. <i>International Journal of Molecular Sciences</i> , 2019, 20, 2887.	4.1	25

#	ARTICLE	IF	CITATIONS
37	Long Noncoding RNA and Epithelial Mesenchymal Transition in Cancer. <i>International Journal of Molecular Sciences</i> , 2019, 20, 1924.	4.1	126
38	Dermoscopic similarity is an independent predictor of <i>BRAF</i> mutational concordance in multiple melanomas. <i>Experimental Dermatology</i> , 2019, 28, 829-835.	2.9	4
39	Inhibition of BET Proteins and Histone Deacetylase (HDACs): Crossing Roads in Cancer Therapy. <i>Cancers</i> , 2019, 11, 304.	3.7	56
40	&lt;p&gt;Approaches to Tumor Classification in Pulmonary Sarcomatoid Carcinoma&lt;/p&gt;. <i>Lung Cancer: Targets and Therapy</i> , 2019, Volume 10, 131-149.	2.7	31
41	An Epithelial-to-Mesenchymal Transcriptional Switch Triggers Evolution of Pulmonary Sarcomatoid Carcinoma (PSC) and Identifies Dasatinib as New Therapeutic Option. <i>Clinical Cancer Research</i> , 2019, 25, 2348-2360.	7.0	31
42	Expression of NOTCH1 in thyroid cancer is mostly restricted to papillary carcinoma. <i>Endocrine Connections</i> , 2019, 8, 1089-1096.	1.9	5
43	BRD4 and Cancer: going beyond transcriptional regulation. <i>Molecular Cancer</i> , 2018, 17, 164.	19.2	414
44	The bHLH transcription factor DEC1 promotes thyroid cancer aggressiveness by the interplay with NOTCH1. <i>Cell Death and Disease</i> , 2018, 9, 871.	6.3	26
45	Mapping fundamental life elements in papillary thyroid carcinoma tissue. <i>Journal of Instrumentation</i> , 2018, 13, C05018-C05018.	1.2	2
46	Not the same thing: metastatic PTCs have a different background than ATCs. <i>Endocrine Connections</i> , 2018, 7, 1370-1379.	1.9	14
47	Genome-wide profiling identifies the THY1 signature as a distinctive feature of widely metastatic Papillary Thyroid Carcinomas. <i>Oncotarget</i> , 2018, 9, 1813-1825.	1.8	30
48	Computational development of a molecular-based approach to improve risk stratification of endometrial cancer patients. <i>Oncotarget</i> , 2018, 9, 25517-25528.	1.8	6
49	Cadherin-6 promotes EMT and cancer metastasis by restraining autophagy. <i>Oncogene</i> , 2017, 36, 667-677.	5.9	155
50	Role of CBX4 in the Colorectal Carcinoma Metastasis&#x201c;Letter. <i>Cancer Research</i> , 2017, 77, 2548-2549.	0.9	2
51	MUG-Mel2, a novel highly pigmented and well characterized NRAS mutated human melanoma cell line. <i>Scientific Reports</i> , 2017, 7, 2098.	3.3	10
52	Inter-relationship between PD-L1 expression and clinic-pathological features and driver gene mutations in pulmonary sarcomatoid carcinomas. <i>Lung Cancer</i> , 2017, 113, 93-101.	2.0	38
53	Long-term outcomes of central neck dissection for cN0 papillary thyroid carcinoma. <i>American Journal of Otolaryngology - Head and Neck Medicine and Surgery</i> , 2017, 38, 576-581.	1.3	21
54	RUNX2 expression in thyroid and breast cancer requires the cooperation of three non-redundant enhancers under the control of BRD4 and c-JUN. <i>Nucleic Acids Research</i> , 2017, 45, 11249-11267.	14.5	57

#	ARTICLE	IF	CITATIONS
55	Therapeutic potential of the metabolic modulator phenformin in targeting the stem cell compartment in melanoma. <i>Oncotarget</i> , 2017, 8, 6914-6928.	1.8	38
56	Multiple Spitz naevi: the randomly distributed variant. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2016, 30, e37-e39.	2.4	1
57	Autophagy and epithelial-mesenchymal transition: an intricate interplay in cancer. <i>Cell Death and Disease</i> , 2016, 7, e2520-e2520.	6.3	159
58	Deep Sequencing Analysis Reveals That KRAS Mutation Is a Marker of Poor Prognosis in Patients with Pulmonary Sarcomatoid Carcinoma. <i>Journal of Thoracic Oncology</i> , 2016, 11, 1282-1292.	1.1	64
59	The extent of whole-genome copy number alterations predicts aggressive features in primary melanomas. <i>Pigment Cell and Melanoma Research</i> , 2016, 29, 163-175.	3.3	14
60	Contemporary and potential future molecular diagnosis of melanoma. <i>Expert Review of Molecular Diagnostics</i> , 2016, 16, 975-985.	3.1	3
61	Novel Long Non Coding RNA Blackmamba Is Associated to ALK- anaplastic Large Cell Lymphoma. <i>Blood</i> , 2016, 128, 461-461.	1.4	1
62	Driver Gene Mutations in Primary Carcinoids of the Lung: Who Are the Best Candidates for Genetic Next-Generation Sequencing?. <i>Lung</i> , 2015, 193, 859-860.	3.3	0
63	Lymph node melanocytic nevi: Pathogenesis and differential diagnoses, with special reference to p16 reactivity. <i>Pathology Research and Practice</i> , 2015, 211, 381-388.	2.3	22
64	A novel BRAF mutation in association with primary amelanotic melanoma with oral metastases. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2015, 29, 387-390.	2.4	5
65	Molecular Testing of Thyroid Fine-Needle Aspirations Improves Presurgical Diagnosis and Supports the Histologic Identification of Minimally Invasive Follicular Thyroid Carcinomas. <i>Thyroid</i> , 2015, 25, 401-409.	4.5	66
66	TERT promoter mutations are associated with distant metastases in papillary thyroid carcinoma. <i>European Journal of Endocrinology</i> , 2015, 172, 403-413.	3.7	115
67	Adding variables to complexity. Molecular imaging and molecular biology: a no-longer-secret liaison in NETs. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2015, 42, 1339-1340.	6.4	0
68	TERT Promoter Mutations in Papillary Thyroid Microcarcinomas. <i>Thyroid</i> , 2015, 25, 1013-1019.	4.5	86
69	Histone Deacetylase Inhibitors Repress Tumoral Expression of the Proinvasive Factor RUNX2. <i>Cancer Research</i> , 2015, 75, 1868-1882.	0.9	28
70	Time to reconsider the meaning of BRAF V600E mutation in papillary thyroid carcinoma. <i>International Journal of Cancer</i> , 2015, 137, 1001-1011.	5.1	44
71	Novel Therapeutic Strategy in the Management of COPD: A Systems Medicine Approach. <i>Current Medicinal Chemistry</i> , 2015, 22, 3655-3675.	2.4	15
72	High-Sensitivity BRAF Mutation Analysis: BRAF V600E Is Acquired Early During Tumor Development but Is Heterogeneously Distributed in a Subset of Papillary Thyroid Carcinomas. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014, 99, E1530-E1538.	3.6	64

#	ARTICLE	IF	CITATIONS
73	Update on Anaplastic Thyroid Carcinoma: Morphological, Molecular, and Genetic Features of the Most Aggressive Thyroid Cancer. <i>International Journal of Endocrinology</i> , 2014, 2014, 1-13.	1.5	130
74	Deep sequencing of KIT, MET, PIK3CA, and PTEN hotspots in papillary thyroid carcinomas with distant metastases. <i>Endocrine-Related Cancer</i> , 2014, 21, L23-L26.	3.1	9
75	CDX2 Expression in Columnar Variant of Papillary Thyroid Carcinoma. <i>Thyroid</i> , 2013, 23, 1498-1499.	4.5	10
76	Papillary thyroid microcarcinoma associated with metastasis and fatal outcome: is the microcarcinoma an incidental finding? reply. <i>Human Pathology</i> , 2013, 44, 1962-1963.	2.0	2
77	Allele Percentage of the <i>BRAF</i> V600E Mutation in Papillary Thyroid Carcinomas and Corresponding Lymph Node Metastases: No Evidence for a Role in Tumor Progression. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013, 98, E934-E942.	3.6	56
78	Papillary thyroid microcarcinoma with fatal outcome: evidence of tumor progression in lymph node metastases. <i>Human Pathology</i> , 2013, 44, 556-565.	2.0	40
79	<i>BRAF</i> V600E Mutation and Papillary Thyroid Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2013, 310, 534.	7.4	4
80	Cadherin 6 Is a New RUNX2 Target in TGF- $\beta$ 2 Signalling Pathway. <i>PLoS ONE</i> , 2013, 8, e75489.	2.5	52
81	Runx2 Isoform I Controls a Panel of Proinvasive Genes Driving Aggressiveness of Papillary Thyroid Carcinomas. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012, 97, E2006-E2015.	3.6	43
82	<i>BRAF</i> V600E Mutation Does Not Mean Distant Metastasis in Thyroid Papillary Carcinomas. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012, 97, E1745-E1749.	3.6	66
83	Epidermal growth factor receptor (EGFR) gene copy number in colorectal adenoma-carcinoma progression. <i>Cancer Genetics</i> , 2012, 205, 630-635.	0.4	9
84	Soluble epidermal growth factor receptor isoforms in non-small cell lung cancer tissue and in blood. <i>Lung Cancer</i> , 2012, 76, 332-338.	2.0	16
85	Inhibitor of DNA binding-1 induces mesenchymal features and promotes invasiveness in thyroid tumour cells. <i>European Journal of Cancer</i> , 2011, 47, 934-945.	2.8	33
86	Tollip Is a Mediator of Protein Sumoylation. <i>PLoS ONE</i> , 2009, 4, e4404.	2.5	29
87	Id1 restrains myeloid commitment, maintaining the self-renewal capacity of hematopoietic stem cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2007, 104, 1260-1265.	7.1	124
88	Bone marrow-derived endothelial progenitor cells are a major determinant of nascent tumor neovascularization. <i>Genes and Development</i> , 2007, 21, 1546-1558.	5.9	360
89	Id1 Restrains p21 Expression to Control Endothelial Progenitor Cell Formation. <i>PLoS ONE</i> , 2007, 2, e1338.	2.5	66
90	Therapy-Induced Acute Recruitment of Circulating Endothelial Progenitor Cells to Tumors. <i>Science</i> , 2006, 313, 1785-1787.	12.6	543

#	ARTICLE	IF	CITATIONS
91	Induction of Complete Regressions of Oncogene-induced Breast Tumors in Mice. Cold Spring Harbor Symposia on Quantitative Biology, 2005, 70, 375-381.	1.1	9
92	Stage-specific gene expression in early differentiating oligodendrocytes. Glia, 2002, 39, 114-123.	4.9	9
93	Editorial: Molecular Characterization of Thyroid Lesions in the Era of "Next-Generation" Techniques. Frontiers in Endocrinology, 0, 13, .	3.5	0